Trial · NCT02623426
Participant flow15
How many started, completed or left each group, period by period.
1 to 15 of 15
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ozurdex (0.7 mg Dexamethasone Pellet) Delivered Via Intravitreal Injection | 65 | 77 |
| Overall Study | STARTED | Intravitreal Methotrexate 400 µg in 0.1 mL 0.9% Sodium Chloride Solution, Preservative-free | 65 | 79 |
| Overall Study | STARTED | Intravitreal Ranibizumab (Lucentis) 0.5 mg in 0.05 mL | 64 | 69 |
| Overall Study | 4 Week Visit | Ozurdex (0.7 mg Dexamethasone Pellet) Delivered Via Intravitreal Injection | 65 | 77 |
| Overall Study | 4 Week Visit | Intravitreal Methotrexate 400 µg in 0.1 mL 0.9% Sodium Chloride Solution, Preservative-free | 64 | 78 |
| Overall Study | 4 Week Visit | Intravitreal Ranibizumab (Lucentis) 0.5 mg in 0.05 mL | 63 | 68 |
| Overall Study | 8 Week Visit | Ozurdex (0.7 mg Dexamethasone Pellet) Delivered Via Intravitreal Injection | 65 | 77 |
| Overall Study | 8 Week Visit | Intravitreal Methotrexate 400 µg in 0.1 mL 0.9% Sodium Chloride Solution, Preservative-free | 64 | 78 |
| Overall Study | 8 Week Visit | Intravitreal Ranibizumab (Lucentis) 0.5 mg in 0.05 mL | 61 | 66 |
| Overall Study | COMPLETED | Ozurdex (0.7 mg Dexamethasone Pellet) Delivered Via Intravitreal Injection | 64 | 76 |
| Overall Study | COMPLETED | Intravitreal Methotrexate 400 µg in 0.1 mL 0.9% Sodium Chloride Solution, Preservative-free | 63 | 77 |
| Overall Study | COMPLETED | Intravitreal Ranibizumab (Lucentis) 0.5 mg in 0.05 mL | 61 | 66 |
| Overall Study | NOT COMPLETED | Ozurdex (0.7 mg Dexamethasone Pellet) Delivered Via Intravitreal Injection | 1 | 1 |
| Overall Study | NOT COMPLETED | Intravitreal Methotrexate 400 µg in 0.1 mL 0.9% Sodium Chloride Solution, Preservative-free | 2 | 2 |
| Overall Study | NOT COMPLETED | Intravitreal Ranibizumab (Lucentis) 0.5 mg in 0.05 mL | 3 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02623426/flow